Physician profile
Amber L Sharp
NPI 1164056644
$1,189.31
in general payments reported to CMS, 2019-2025
21 companies · $99.33 in 2025
The $99.33 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $549 · 2022: $322 · 2023: $53.87 · 2024: $165 · 2025: $99.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $318.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $260.30 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $140.05 | 2021-2024 | Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $115.83 | 2021-2025 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.28 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.08 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $54.51 | 2021 | |
| Eisai INC. | $49.58 | 2021-2022 | |
| Indivior INC. | $49.39 | 2024 | Sublocade |
| Alkermes, INC. | $45.45 | 2024-2025 | Vivitrol |
| Dexcom, INC. | $42.07 | 2021-2022 | |
| Astellas Pharma US INC | $39.86 | 2021 | |
| Pfizer INC. | $39.86 | 2021-2022 | |
| Abbvie INC. | $36.67 | 2022-2025 | |
| Avanir Pharmaceuticals, INC. | $34.01 | 2021 | |
| Amgen INC. | $33.40 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $23.64 | 2022 | |
| Amarin Pharma, INC. | $18.92 | 2021 | |
| Braeburn INC. | $18.02 | 2024 | Brixadi |
| Sanofi-Aventis U.S. LLC | $17.97 | 2021 | |
| Medtronic, INC. | $13.00 | 2022 | |
| Merck Sharp & Dohme LLC | $12.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.